









Markets
/
Stocks
/
nasdaq-lyel
/

Lyell Immunopharma Inc

LYEL

22.710USD

+0.070+0.31%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

438.17MMarket Cap

LossP/E TTM



Lyell Immunopharma Inc

22.710

+0.070+0.31%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lyell Immunopharma Inc

Currency: USD Updated: 2026-02-06

Key Insights

Lyell Immunopharma Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 131 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 38.50.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lyell Immunopharma Inc's Score

Industry at a Glance

Industry Ranking

131 / 392

Overall Ranking

269 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Lyell Immunopharma Inc Highlights

StrengthsRisks

Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Growing

The company is in a growing phase, with the latest annual income totaling USD 61.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 61.00K.

Fairly Valued

The company’s latest PE is -1.00, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 10.68M shares, increasing 0.28% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 826.43K shares of this stock.

Analyst Rating

Based on 3 analysts

Hold

Current Rating

38.500

Target Price

+59.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Lyell Immunopharma Inc is 6.05, ranking 295 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 15.00K, representing a year-over-year decrease of 55.88%, while its net profit experienced a year-over-year decrease of 12.87%.

Score

Industry at a Glance

Previous score

6.05

Change



Financials

8.10

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.95

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Lyell Immunopharma Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Lyell Immunopharma Inc is 8.60, ranking 35 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.00, which is -98.68% below the recent high of -0.01 and -435.71% above the recent low of -5.34.

Score

Industry at a Glance

Previous score

8.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 131/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Lyell Immunopharma Inc is 6.67, ranking 330 out of 392 in the Biotechnology & Medical Research industry. The average price target is 25.00, with a high of 45.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

6.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Hold

Current Rating

38.500

Target Price

+59.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Lyell Immunopharma Inc

LYEL

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Lyell Immunopharma Inc is 6.87, ranking 148 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 26.40 and the support level at 20.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.86

Change

0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.160

Sell

RSI(14)

39.624

Neutral

STOCH(KDJ)(9,3,3)

20.447

Sell

ATR(14)

1.874

High Vlolatility

CCI(14)

-157.077

Sell

Williams %R

87.945

Oversold

TRIX(12,20)

-0.670

Sell

StochRSI(14)

3.012

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

24.014

Sell

MA10

24.309

Sell

MA20

24.219

Sell

MA50

27.395

Sell

MA100

21.967

Buy

MA200

16.049

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Lyell Immunopharma Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 50.29%, representing a quarter-over-quarter decrease of 2.72%. The largest institutional shareholder is The Vanguard, holding a total of 826.43K shares, representing 3.89% of shares outstanding, with 17.96% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARCH Venture Partners

2.76M

+51.54%

Innovative Cellular Therapeutics Holdings Ltd

1.90M

GSK plc

1.51M

Foresite Capital Management, LLC

1.28M

+5.83%

Gates Frontier, L.L.C.

1.04M

Explore Investments LLC

1.04M

MWG Management, Ltd.

1.01M

The Vanguard Group, Inc.

Star Investors

779.00K

+76.00%

Orland Properties Ltd

754.70K

Decheng Capital LLC

595.47K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lyell Immunopharma Inc is 2.20, ranking 246 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.14. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.